PCSK9 Inhibition could be Effective for Acute Myocardial Infarction.

Gencer, Baris; Mach, François (2022). PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. Current medicinal chemistry, 29(6), pp. 1016-1026. Bentham 10.2174/0929867328666210804091003

Full text not available from this repository. (Request a copy)

In this review, we explore the role of PCSK9 and the inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidencebased therapies to improve outcomes, one-year mortality remains at 12-15%, and there is still a need to further reduce complications related to MI. Mechanistic and epidemiologic studies have suggested that the naturally occurring PCSK9 protein increases coronary plaque vulnerability through several pathways, including pro-inflammatory LDL-C oxidation and direct modification of plaque composition. PCSK9 inhibitors are a class of drugs with proven efficacy in patients with recent MI. The latest guidelines recommend the use of PCSK9 inhibitors in patients with recent MI early in the process of care to reduce LDL-C values and associated morbidity. The use of PCSK9 inhibition could be beneficial for mortality reduction after an acute MI and should be tested in an appropriately powered randomized controlled trial.

Item Type:	Journal Article (Review Article)
Division/Institute:	04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)
UniBE Contributor:	Gencer, Baris Faruk
Subjects:	600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services
ISSN:	0929-8673
Publisher:	Bentham
Language:	English
Submitter:	Doris Kopp Heim
Date Deposited:	15 Mar 2022 17:31
Last Modified:	05 Dec 2022 16:15
Publisher DOI:	10.2174/0929867328666210804091003
PubMed ID:	34348606
Uncontrolled Keywords:	Lipids PCSK9. acute coronary syndromes cardiovascular disease lipid-lowering myocardial infarction
URI:	https://boris.unibe.ch/id/eprint/167448